Interactions of selected flavonoids with mesalazine and budesonide in CCD18-Co cells and DSS-induced colitis model / Omar AbdulHafiz AlHarasstani

Background and Objective: Although some phytochemicals demonstrate a wide range of health benefits, thought to be by directly targeting the underlying cascades responsible for the production of key pro-inflammatory mediators involved in inflammatory bowel disease (IBD), no study has compared the eff...

Full description

Saved in:

Bibliographic Details
Main Author:	AlHarasstani, Omar AbdulHafiz
Format:	Thesis
Language:	English
Published:	2022
Subjects:	Cancer Materia medica and pharmacology
Online Access:	https://ir.uitm.edu.my/id/eprint/66998/1/66998.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

id	my-uitm-ir.66998
record_format	uketd_dc
spelling	my-uitm-ir.669982022-09-20T05:18:36Z Interactions of selected flavonoids with mesalazine and budesonide in CCD18-Co cells and DSS-induced colitis model / Omar AbdulHafiz AlHarasstani 2022 AlHarasstani, Omar AbdulHafiz Cancer Materia medica and pharmacology Background and Objective: Although some phytochemicals demonstrate a wide range of health benefits, thought to be by directly targeting the underlying cascades responsible for the production of key pro-inflammatory mediators involved in inflammatory bowel disease (IBD), no study has compared the efficacy of current IBD treatments with such phytochemicals and their combinations or the possible drug-drug synergism that would be applicable to IBD treatment. This study therefore aimed to compare the interactions of selected promising natural phytochemicals which have been assessed in recent years for their therapeutic potentials, namely gallic acid (trihydroxybenzoic acid), thymoquinone, and bryonolic acid and their combinations, with current IBD treatments such as aminosalicylates (mesalazine) and corticosteroids (budesonide) in in vitro model and in an acute DSS-induced colitis animal model utilizing modern isobolographic analysis. Recent research employed in vitro screening of anti-inflammatory activities of phytochemicals using CCD18-Co human colon fibroblast cell line which was employed as the in vitro model in this study. Cells were treated with the selected phytochemicals either individually or in combination with current IBD treatments (mesalazine and budesonide) and co-stimulated with LPS for selected cytokines assays to detect synergistic response of the following cytokines: IL-2, IL-4, IL-6, IL-10, IL-17A, IL-23, TNF-α, IFN-γ and PGE2. For the in vivo study, induction of colitis in mice was achieved by daily challenge with 5% DSS in drinking water for 7 days. Mice groups were orally treated with different drugs and/or combinations on a daily basis. Disease scores (bleeding, diarrhoea and stool consistency) was observed, systemic effects (total body weight loss, serum cytokine levels and anti-neutrophil cytoplasm antibodies (ANCAs) levels were quantified by flow cytometry and ELISA assays, colonic tissue myeloperoxidase (MPO) activity was measured by standard colourimetric assay, histopathology, inflammatory parameters such as erythrocyte sedimentation rate, C-reactive protein, and faecal calprotectin were measured using conventional ELISA method and flow cytometry. Results showed that all flavonoids had efficacy in vitro & in vivo, of the three flavonoids tested, thymoquinone is the most efficacious compared to gallic acid while bryonolic acid was the least efficacious. Current treatment of mesalazine and budesonide are efficacious in both in vitro & in vivo models. The three flavonoids showed synergistic effect with mesalazine or budesonide on multiple parameters, however, the most significant synergism was observed between thymoquinone and mesalazine or thymoquinone and budesonide. The two standard treatments mesalazine and budesonide synergize with each other. All flavonoids (thymoquinone, gallic acid and bryonolic acid) showed inhibition of pro-inflammatory cytokines in vitro & in vivo but, the most potent is thymoquinone, accounting for its significant synergism with mesalazine and budesonide, resulting in clinical improvement of DSS-challenged acute colitis mice with the underlying shift of the immune paradigm towards Th2 mediated response while enhancing the expression of Th2 anti-inflammatory cytokines. Thus, nominating thymoquinone as a promising adjunctive therapy to mesalazine or budesonide for IBD and UC. 2022 Thesis https://ir.uitm.edu.my/id/eprint/66998/ https://ir.uitm.edu.my/id/eprint/66998/1/66998.pdf text en public phd doctoral Universiti Teknologi MARA (UiTM) Faculty of Pharmacy Hazizul Hasan, Mizaton
institution	Universiti Teknologi MARA
collection	UiTM Institutional Repository
language	English
advisor	Hazizul Hasan, Mizaton
topic	Cancer Materia medica and pharmacology
spellingShingle	Cancer Materia medica and pharmacology AlHarasstani, Omar AbdulHafiz Interactions of selected flavonoids with mesalazine and budesonide in CCD18-Co cells and DSS-induced colitis model / Omar AbdulHafiz AlHarasstani
description	Background and Objective: Although some phytochemicals demonstrate a wide range of health benefits, thought to be by directly targeting the underlying cascades responsible for the production of key pro-inflammatory mediators involved in inflammatory bowel disease (IBD), no study has compared the efficacy of current IBD treatments with such phytochemicals and their combinations or the possible drug-drug synergism that would be applicable to IBD treatment. This study therefore aimed to compare the interactions of selected promising natural phytochemicals which have been assessed in recent years for their therapeutic potentials, namely gallic acid (trihydroxybenzoic acid), thymoquinone, and bryonolic acid and their combinations, with current IBD treatments such as aminosalicylates (mesalazine) and corticosteroids (budesonide) in in vitro model and in an acute DSS-induced colitis animal model utilizing modern isobolographic analysis. Recent research employed in vitro screening of anti-inflammatory activities of phytochemicals using CCD18-Co human colon fibroblast cell line which was employed as the in vitro model in this study. Cells were treated with the selected phytochemicals either individually or in combination with current IBD treatments (mesalazine and budesonide) and co-stimulated with LPS for selected cytokines assays to detect synergistic response of the following cytokines: IL-2, IL-4, IL-6, IL-10, IL-17A, IL-23, TNF-α, IFN-γ and PGE2. For the in vivo study, induction of colitis in mice was achieved by daily challenge with 5% DSS in drinking water for 7 days. Mice groups were orally treated with different drugs and/or combinations on a daily basis. Disease scores (bleeding, diarrhoea and stool consistency) was observed, systemic effects (total body weight loss, serum cytokine levels and anti-neutrophil cytoplasm antibodies (ANCAs) levels were quantified by flow cytometry and ELISA assays, colonic tissue myeloperoxidase (MPO) activity was measured by standard colourimetric assay, histopathology, inflammatory parameters such as erythrocyte sedimentation rate, C-reactive protein, and faecal calprotectin were measured using conventional ELISA method and flow cytometry. Results showed that all flavonoids had efficacy in vitro & in vivo, of the three flavonoids tested, thymoquinone is the most efficacious compared to gallic acid while bryonolic acid was the least efficacious. Current treatment of mesalazine and budesonide are efficacious in both in vitro & in vivo models. The three flavonoids showed synergistic effect with mesalazine or budesonide on multiple parameters, however, the most significant synergism was observed between thymoquinone and mesalazine or thymoquinone and budesonide. The two standard treatments mesalazine and budesonide synergize with each other. All flavonoids (thymoquinone, gallic acid and bryonolic acid) showed inhibition of pro-inflammatory cytokines in vitro & in vivo but, the most potent is thymoquinone, accounting for its significant synergism with mesalazine and budesonide, resulting in clinical improvement of DSS-challenged acute colitis mice with the underlying shift of the immune paradigm towards Th2 mediated response while enhancing the expression of Th2 anti-inflammatory cytokines. Thus, nominating thymoquinone as a promising adjunctive therapy to mesalazine or budesonide for IBD and UC.
format	Thesis
qualification_name	Doctor of Philosophy (PhD.)
qualification_level	Doctorate
author	AlHarasstani, Omar AbdulHafiz
author_facet	AlHarasstani, Omar AbdulHafiz
author_sort	AlHarasstani, Omar AbdulHafiz
title	Interactions of selected flavonoids with mesalazine and budesonide in CCD18-Co cells and DSS-induced colitis model / Omar AbdulHafiz AlHarasstani
title_short	Interactions of selected flavonoids with mesalazine and budesonide in CCD18-Co cells and DSS-induced colitis model / Omar AbdulHafiz AlHarasstani
title_full	Interactions of selected flavonoids with mesalazine and budesonide in CCD18-Co cells and DSS-induced colitis model / Omar AbdulHafiz AlHarasstani
title_fullStr	Interactions of selected flavonoids with mesalazine and budesonide in CCD18-Co cells and DSS-induced colitis model / Omar AbdulHafiz AlHarasstani
title_full_unstemmed	Interactions of selected flavonoids with mesalazine and budesonide in CCD18-Co cells and DSS-induced colitis model / Omar AbdulHafiz AlHarasstani
title_sort	interactions of selected flavonoids with mesalazine and budesonide in ccd18-co cells and dss-induced colitis model / omar abdulhafiz alharasstani
granting_institution	Universiti Teknologi MARA (UiTM)
granting_department	Faculty of Pharmacy
publishDate	2022
url	https://ir.uitm.edu.my/id/eprint/66998/1/66998.pdf
_version_	1783735654529630208

Interactions of selected flavonoids with mesalazine and budesonide in CCD18-Co cells and DSS-induced colitis model / Omar AbdulHafiz AlHarasstani

Similar Items